Independent of the presence of bone metastases, patients with an EGFR mutation had a significantly higher EGFR expression, compared to patients with a KRAS+ or EGFR/KRAS wildtype NSCLC (p<0.001) (Supplementary Material, Figure 1A). This evidence concerns the gene EGFR and non-small cell lung carcinoma.